Bladder Cancer market Growth Trend & Forecast with latest research study released by Delvens evaluating the market risk side analysis, highlighting opportunities, and leveraging strategic and tactical decision-making support. The report provides information on market trends and development, growth drivers, technologies, and the changing investment structure of the Global Bladder Cancer market.
The global Bladder Cancer market size was estimated at USD 5.25 billion in 2023 and is projected to reach USD 7.52 billion in 2030 at a CAGR of 4.60% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/bladder-cancer-market
Bladder cancer occurs when the cells that make up the bladder begin to multiply uncontrollably. More cancer cells can form a tumor and spread to other parts of the body over time. The bladder wall consists of several layers. Each layer consists of several types of cells. The urothelium, or transitional epithelium, lining the inside of the bladder is where most bladder malignancies begin.
The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer.
Regional Analysis
North America to Dominate the Market
• North America is estimated to account for the largest market share during the forecast period. Due to the region's expanding R&D activities and well-established healthcare infrastructure.
• Moreover, the existence of numerous biologics and biopharmaceutical firms is another factor that has contributed to the bladder cancer therapies and diagnostics market's size and stellar growth.
Competitive Landscape
• Abbott Inc.
• Accord Healthcare
• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bedford Lab
• Bristol-Myers Squibb Company
• Celgene Corporation
• Eli Lilly and Company
• Endo Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Hoffmann-La Roche AG
• Johnson & Johnson (Janssen Pharmaceutical)
• Merck & Co. Inc
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A. and More
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/bladder-cancer-market
Recent Developments
• In July 2022, The United States Food and Drug Administration (FDA) agreed to review ImmunityBio's Biologics License Application (BLA) for N-803 in patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).
• In July 2022, Nanostics Inc., launched a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX diagnostic platform. In partnership with the University of Alberta’s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs.
The Bladder Cancer Market is segmented into various segments such as type, Treatment, diagnosis, end user, and region:
Based on Type
• Transitional Cell Carcinoma
• Invasive Bladder Cancer
• Superficial Bladder Cancer
• Adenocarcinomax
• Other Rare Types
Based on the Treatment
• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Radical Cystectomy
• Others
Based on the Diagnosis
• Urine Lab Tests
• Cystoscopy
• Biopsy
• Imaging Test
• Others
Based on End User
• Hospital
• Clinic
• Cancer Care Centers
• Others
Access Full Report: https://www.delvens.com/report/bladder-cancer-market
In addition to the market data for the Bladder Cancer Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
More Reports from Delvens:
Multiple Sclerosis (MS) market size was estimated at USD 25.2 billion in 2023 and is projected to reach USD 34.9 billion in 2030 at a CAGR of 4.76% during the forecast period 2023-2030.
Plastic Surgery and Integumentary System Market size was estimated at USD 3.02 billion in 2023 and is projected to reach USD 4.3 billion in 2030 at a CAGR of 5.2% during the forecast period 2023-2030.
Pain Relief Gel market size was estimated at USD 10.4 billion in 2023 and is projected to reach USD 15.3 billion in 2030 at a CAGR of 5.2% during the forecast period 2023-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
[email protected]